INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation
FRA:IUI1 • US46120E6023
Current stock price
398.4 EUR
-7 (-1.73%)
Last:
This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IUI1.DE Profitability Analysis
1.1 Basic Checks
- IUI1 had positive earnings in the past year.
- In the past year IUI1 had a positive cash flow from operations.
- Each year in the past 5 years IUI1 has been profitable.
- IUI1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IUI1's Return On Assets of 13.96% is amongst the best of the industry. IUI1 outperforms 98.28% of its industry peers.
- IUI1's Return On Equity of 16.02% is amongst the best of the industry. IUI1 outperforms 87.93% of its industry peers.
- IUI1 has a better Return On Invested Capital (13.95%) than 91.38% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is above the industry average of 9.41%.
- The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROIC | 13.95% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
1.3 Margins
- Looking at the Profit Margin, with a value of 28.38%, IUI1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Profit Margin of IUI1 has grown nicely.
- IUI1 has a better Operating Margin (29.35%) than 100.00% of its industry peers.
- IUI1's Operating Margin has improved in the last couple of years.
- With a decent Gross Margin value of 66.00%, IUI1 is doing good in the industry, outperforming 75.86% of the companies in the same industry.
- In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% |
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
2. IUI1.DE Health Analysis
2.1 Basic Checks
- IUI1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, IUI1 has less shares outstanding
- IUI1 has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 39.54 indicates that IUI1 is not in any danger for bankruptcy at the moment.
- IUI1 has a Altman-Z score of 39.54. This is amongst the best in the industry. IUI1 outperforms 100.00% of its industry peers.
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 39.54 |
ROIC/WACC1.55
WACC9%
2.3 Liquidity
- A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
- IUI1's Current ratio of 4.87 is amongst the best of the industry. IUI1 outperforms 94.83% of its industry peers.
- IUI1 has a Quick Ratio of 3.96. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.96, IUI1 belongs to the top of the industry, outperforming 96.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 |
3. IUI1.DE Growth Analysis
3.1 Past
- IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.92%, which is quite impressive.
- IUI1 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.42% yearly.
- Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
- Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)25.92%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%38.12%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%22.96%
3.2 Future
- IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.55% yearly.
- The Revenue is expected to grow by 13.00% on average over the next years. This is quite good.
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.55%
Revenue Next Year15.78%
Revenue Next 2Y14.84%
Revenue Next 3Y14.6%
Revenue Next 5Y13%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IUI1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- IUI1 is valuated quite expensively with a Price/Earnings ratio of 48.35.
- IUI1's Price/Earnings is on the same level as the industry average.
- When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (26.91), we can say IUI1 is valued expensively.
- Based on the Price/Forward Earnings ratio of 39.89, the valuation of IUI1 can be described as expensive.
- Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 67.24% of the companies are valued more cheaply.
- The average S&P500 Price/Forward Earnings ratio is at 21.99. IUI1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.35 | ||
| Fwd PE | 39.89 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 65.52% of the companies in the same industry.
- IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.36 | ||
| EV/EBITDA | 43.12 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of IUI1 may justify a higher PE ratio.
- A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.44% in the coming years.
PEG (NY)3.35
PEG (5Y)2.26
EPS Next 2Y14.29%
EPS Next 3Y14.44%
5. IUI1.DE Dividend Analysis
5.1 Amount
- IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IUI1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IUI1 (4/28/2026, 7:00:00 PM)
398.4
-7 (-1.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength10.56
Industry Growth62.11
Earnings (Last)04-21 2026-04-21/amc
Earnings (Next)07-20 2026-07-20/amc
Inst Owners88.75%
Inst Owner ChangeN/A
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap141.50B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts79.02
Price Target525.27 (31.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-0.42%
PT rev (3m)-1.16%
EPS NQ rev (1m)-0.79%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.86%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-0.07%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.35 | ||
| Fwd PE | 39.89 | ||
| P/S | 16.42 | ||
| P/FCF | 66.36 | ||
| P/OCF | 54.54 | ||
| P/B | 9.27 | ||
| P/tB | 9.48 | ||
| EV/EBITDA | 43.12 |
EPS(TTM)8.24
EY2.07%
EPS(NY)9.99
Fwd EY2.51%
FCF(TTM)6
FCFY1.51%
OCF(TTM)7.31
OCFY1.83%
SpS24.26
BVpS42.97
TBVpS42.03
PEG (NY)3.35
PEG (5Y)2.26
Graham Number89.252 (-77.6%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROCE | 16.01% | ||
| ROIC | 13.95% | ||
| ROICexc | 20.73% | ||
| ROICexgc | 21.4% | ||
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% | ||
| FCFM | 24.75% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 79.72% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.46% | ||
| Profit Quality | 87.21% | ||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z | 39.54 |
F-Score8
WACC9%
ROIC/WACC1.55
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)25.92%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%38.12%
EPS Next Y14.43%
EPS Next 2Y14.29%
EPS Next 3Y14.44%
EPS Next 5Y13.55%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%22.96%
Revenue Next Year15.78%
Revenue Next 2Y14.84%
Revenue Next 3Y14.6%
Revenue Next 5Y13%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.45%
EBIT Next 3Y21.62%
EBIT Next 5Y17.23%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%
INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
What is the profitability of IUI1 stock?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.
How financially healthy is INTUITIVE SURGICAL INC?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.
What is the expected EPS growth for INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 14.43% in the next year.